Companies › Jiangxi Qingfeng Pharmaceutical
1 active drug program in 2 registered trials: 2 Phase 3; Infectious disease; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GP681 Neuraminidase inhibitor | – | Phase 3 | Influenza, Human; Influenza | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06573008 | GP681 | Phase 3 | Influenza, Human | Infectious disease | Dec 2025 |
| NCT06574503 | GP681 | Phase 3 | Influenza | Infectious disease | Jul 2027 |
No annotated target.
–
Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.